These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1798 related items for PubMed ID: 29677303
1. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. JAMA; 2018 Apr 17; 319(15):1580-1591. PubMed ID: 29677303 [Abstract] [Full Text] [Related]
4. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. Kramer CK, Ye C, Campbell S, Retnakaran R. JACC Heart Fail; 2018 Oct 17; 6(10):823-830. PubMed ID: 30196071 [Abstract] [Full Text] [Related]
8. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N. Prim Care Diabetes; 2019 Jun 17; 13(3):204-211. PubMed ID: 30713085 [Abstract] [Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Cochrane Database Syst Rev; 2021 Oct 25; 10(10):CD013650. PubMed ID: 34693515 [Abstract] [Full Text] [Related]
11. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT. JAMA Netw Open; 2018 Dec 07; 1(8):e186125. PubMed ID: 30646315 [Abstract] [Full Text] [Related]
15. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. Grenet G, Ribault S, Nguyen GB, Glais F, Metge A, Linet T, Kassai-Koupai B, Cornu C, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Gouraud A, Bonnet F, Cucherat M, Moulin P, Gueyffier F. PLoS One; 2019 Dec 07; 14(6):e0217701. PubMed ID: 31237921 [Abstract] [Full Text] [Related]
16. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Scheen AJ. Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368 [Abstract] [Full Text] [Related]
17. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Lin DS, Lee JK, Hung CS, Chen WJ. Diabetologia; 2021 Dec 11; 64(12):2676-2686. PubMed ID: 34536085 [Abstract] [Full Text] [Related]
19. Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks. Pai YW, Chen IC, Lin JF, Chen XH, Chen HH, Chang MH, Huang JA, Lin CH. Diabetes Obes Metab; 2024 Nov 11; 26(11):5420-5430. PubMed ID: 39248211 [Abstract] [Full Text] [Related]